当前位置：首页>产品中心>单抗/多抗>Anti-Human 4-1BB Ligand/TNFSF9 Reference Antibody|抗人4-1BB配体/TNFSF9参考抗体(靶标：人4-1BB配体（TNFSF9）)
Anti-Human 4-1BB Ligand/TNFSF9 Reference Antibody|抗人4-1BB配体/TNFSF9参考抗体(靶标：人4-1BB配体（TNFSF9）)
- 货号：RB9THC336126
- 价格：面议
- 点击：303
产品介绍
产品参数
| 形态 | Liquid |
|---|---|
| 宿主种属 | Human |
| 克隆性 | Monoclonal |
| 抗体亚型 | IgG1-kappa |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| 浓度 | 1mg/ml |
| 内毒素水平 | Please contact the lab for this information. |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 种属反应性 | Human |
| 靶标 | Tumor necrosis factor receptor superfamily member 9, CD137, 4-1BB ligand receptor, CDw137, TNFRSF9, T-cell antigen ILA, T-cell antigen 4-1BB homolog, ILA |
| 储存缓冲液 | 0.01M PBS, pH 7.4. |
| 稳定性和储存 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 表达系统 | Mammalian Cells |
| 登录号 | Q07011 |
| 背景信息 | Urelumab is a fully humanized agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. Urelumab specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells. Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer-Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb-derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex. In December 2008, enrolment was stopped for all urelumab studies following the occurrence of two hepatotoxicity-related deaths. Several years later, the clinical study on Urelumab was restarted. At present, the approval of the monoclonal antibody has not been disclosed in the relevant drug approval agency. • Analysis of 4-1BBL and laminin binding to murine 4-1BB, a member of the tumor necrosis factor receptor superfamily, and comparison with human 4-1BB., PMID:9045669 • ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages., PMID:7849293 • CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes., PMID:10607752 • CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling., PMID:9498794 • A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis., PMID:9485208 • CD137-induced apoptosis is independent of CD95., PMID:10469232 • CD137 activation abrogates granulocyte-macrophage colony-stimulating factor-mediated anti-apoptosis in neutrophils., PMID:11093162 • Expression of CD137 and its ligand in human neurons, astrocytes, and microglia: modulation by FGF-2., PMID:13130507 • Comparative analysis of CD137 and LPS effects on monocyte activation, survival, and proliferation., PMID:10873573 • CD137 expression in tumor vessel walls. High correlation with malignant tumors., PMID:11293902 |
| 别名 | 2642171-64-8 |
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
相关产品: